Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 2,739 Shares

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 2,739 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $20.45, for a total transaction of $56,012.55. Following the completion of the sale, the insider owned 57,022 shares of the company’s stock, valued at $1,166,099.90. The trade was a 4.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Rafael Amado also recently made the following trade(s):

• On Thursday, April 2nd, Rafael Amado sold 9,910 shares of Zai Lab stock. The stock was sold at an average price of $20.39, for a total transaction of $202,064.90.
• On Friday, March 13th, Rafael Amado sold 2,957 shares of Zai Lab stock. The stock was sold at an average price of $18.63, for a total transaction of $55,088.91.

Zai Lab Trading Up 1.9%

Shares of Zai Lab stock opened at $21.39 on Thursday. The firm has a fifty day simple moving average of $18.89 and a 200-day simple moving average of $21.51. Zai Lab Limited Unsponsored ADR has a 1-year low of $15.96 and a 1-year high of $44.34. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -13.29 and a beta of 0.86.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Saturday, February 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%.The company had revenue of $127.60 million for the quarter. As a group, research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ZLAB shares. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. Cantor Fitzgerald dropped their target price on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research report on Wednesday, January 21st. UBS Group started coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Finally, JPMorgan Chase & Co. dropped their target price on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

Institutional Investors Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC raised its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,396 shares of the company’s stock after buying an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. Institutional investors and hedge funds own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.